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Abstract 
 
 Individuals with the inherited bleeding disorder hemophilia, have achieved 
tremendous advances in clinical outcomes through widespread implementation of 
prophylactic replacement with safe and efficacious factor VIII and IX.  However, despite this 
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therapeutic approach, bleeds still occur, some with serious consequence, joint disease has 
not been eradicated, and patients have not yet been liberated from the need for regular 
intravenous infusions.  The shift from protein replacement to gene replacement is offering 
great hope to achieve durable levels of plasma factor activity levels high enough to remove 
the risk for recurrent joint bleeding.  For the first time, clinical trial results are showing 
promise for “curative” correction of the bleeding phenotype. 
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Introduction 
 Hemophilia is an X-linked recessive bleeding disorder leading to spontaneous 
bleeding and bleeding following trauma and surgery.  Though typically expressed in males, 
female genetic carriers may have clinical bleeding symptoms and even factor activity levels 
in the hemophilia range.  It is characterized by a congenital deficiency of coagulation factor 
VIII (hemophilia A) and factor IX (hemophilia B) affecting approximately 20,000 individuals in 
the USA and over 400,000 individuals across the globe1,2.  Hemophilia arises from mutations 
in the F8 and F9 genes with an incidence of about 1 in 5000 and 1 in 30,000 male births, 
respectively, with >30% of cases occurring due to spontaneous mutations, and affects all 
racial and ethnic groups3.  Severity is defined by the residual plasma factor activity, with 
those with severe deficiency (<1% activity) accounting for about half of affected individuals.  
Without the availability of replacement therapy, individuals with severe disease are at risk for 
recurrent bleeding into joints (hemarthroses), muscles, soft tissues and other locations that 
can be life-threatening (eg. central nervous system). Long-term sequelae as a result of 
recurrent bleeding include chronic arthropathy, chronic pain, muscle atrophy, and loss of 
mobility with significant disability4. 
The mortality and morbidity of severe hemophilia has been significantly impacted by 
the development of factor VIII (FVIII) and factor IX (FIX) concentrates.  The current standard 
of care is prophylactic factor replacement therapy5,6.  The rationale for prophylaxis was the 
observation that individuals with moderate hemophilia (as little as 1-5% of residual activity) 
exhibited fewer hemarthroses and were much less likely to develop arthropathy4,7.  The 
hypothesis was that regular infusions of factor concentrates with a goal of maintaining a 
plasma activity that did not fall below 1-2% would lead to a more moderate clinical 
phenotype with less joint bleeding and subsequent arthropathy.  Primary prophylaxis initiated 
in infancy and early childhood in the absence of documented joint disease and continued 
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indefinitely has been proven to prevent overall bleeding, joint bleeding and arthropathy and 
has led to health-related quality of life measures that are indistinguishable from their 
unaffected peers. 
 
Hemophilia in the recombinant DNA era 
  The recombinant era for hemophilia began in the 1980s with the cloning of the F8 
and F9 genes and the subsequent expression of functional proteins for both FVIII and FIX 
within mammalian cell lines8. The rationale for recombinant clotting factors included: a) that 
they would be safer than their plasma-derived counterparts, especially as they were being 
developed on the backdrop of the catastrophic viral contamination of plasma-derived clotting 
factors, b) the development of consistent manufacturing and processing that was liberated 
from the uncertainties of securing source plasma, c) a potentially unlimited supply that could 
drive down costs of replacement therapy, d) that this would facilitate an increase in the 
utilization of prophylaxis and e) wider availability of replacement products for patients in 
developing countries.  Over the past 20 years of clinical trial and worldwide experience, 
recombinant clotting factors have not had any infectious pathogen transmission, no safety 
signals on adverse event reporting and no evidence of increased rate of inhibitors in 
previously treated patients9,10.  Further, recombinant DNA technology has facilitated efforts 
that are exploiting insights on the structure and function of FVIII and FIX to introduce 
targeted modifications that enhance their functional properties.  This has best been 
exemplified in a recent wave of bioengineered molecules that have more efficient production 
and purification, optimized post-translational modifications and enhanced 
pharmacokinetics11,12. 
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 The efficient production of recombinant clotting factors in mammalian and eventually 
human cell culture systems required overcoming significant challenges due to the complex 
post-translational modifications that are integral to their procoagulant function8.  In addition, 
preclinical animal models were utilized to conduct pharmacokinetic, efficacy and safety 
evaluations.  These were particularly important to characterize and evaluate bioengineered 
molecules with enhanced properties.  This laid the groundwork for moving from protein-
based replacement therapy to gene-based replacement therapy (Figure 1). 
 
What are the remaining unmet needs? 
 With widespread availability of safe and effective plasma-derived and recombinant 
clotting factors and effective implementation of primary prophylaxis, clinical outcomes in 
hemophilia have made outstanding advances.  However, there are remaining barriers to the 
adoption and adherence to the demands of prophylaxis12.  The protein replacement strategy 
requires venous access from a young age, significant demands in cost and time to patients 
and their caregivers as well as health system access challenges.  Clinicians must adapt 
replacement therapy to a wide range of phenotypic and pharmacokinetic variability.  Long-
term follow up data with current approaches has been limited to 25-30 years but have shown 
that annualized bleeding rates are not zero and joint disease still appears in young 
adults13,14. Thus, what are the implications over a lifetime? 
Individuals with hemophilia may also develop an immune response triggered by 
exposure to the FVIII or FIX protein in any of its forms (plasma-derived or recombinant) and 
these IgG antibodies (inhibitors) neutralize the coagulant effect of the infused factor.  The 
incidence is highest in those with severe disease (20-30% of severe hemophilia A, 1-4% of 
severe hemophilia B)15.  These typically develop early in life (median age 1.7-3.3 years) with 
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the greatest exposure within the first 50 exposure days to the infused product.  Individuals 
with inhibitors must rely on alternative hemostatic agents, bypassing agents (activated 
prothrombin complex concentrates, recombinant factor VIIa), that have unpredictable 
efficacy.  Eradication of the inhibitors can be achieved (in about 70%) through an immune 
tolerance therapy in which high doses of FVIII or FIX are given over a long period to time 
until the antibody has waned.  However, the total cost of treating inhibitors is even more 
significant with increased factor utilization and an adverse impact on clinical outcomes with 
higher mortality and morbidity from joint disease and bleeding16. 
The relatively short half-life of FVIII and FIX leads to the most significant burden of 
treatment with a standard prophylaxis regimen for FVIII of three to four infusions per week 
(two to three infusions per week for FIX)17.  This is what has typically been required to 
maintain trough factor levels above approximately 1%.  Extended half-life versions of FVIII 
and FIX have received FDA approval.  Although the extended half-life FVIII products offer 
very little change in the dosing frequency of infusions, the extended half-life FIX offer the 
possibility of weekly and even every 2 week infusion strategies.   These products have also 
enabled the ability to achieve higher trough levels when clinically indicated with a reasonable 
infusion frequency, and potentially improve adherence to prophylaxis12.  These incremental 
improvements in care may slow the transition away from protein-based replacement therapy 
to gene-based delivery.  Nevertheless, these new therapies have not reduced the cost of 
care for patients and health systems, have not eliminated the burden of regular venous 
access, and it is not known if these will significantly impact the incidence of inhibitors. 
 
Why gene therapy for hemophilia? 
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 Moving from protein replacement to gene replacement overcomes many of the unmet 
challenges to hemophilia care.  Gene therapy would rely on endogenous expression of the 
clotting factor leading to steady state levels and a sustained duration of action.  This would 
liberate individuals from prophylaxis and the need for regular intravenous delivery.  The 
efficacy of the therapy would not be tied to adherence.  This would have the greatest impact 
on the overall burden of therapy.  Endogenous expression of the factors could be less 
immunogenic as they would have altered interaction with the immune system and could 
potentially even be a more effective tolerizing therapy in those with established inhibitors18.  
With current therapy, more than 90% of the overall costs of care for hemophilia is the cost of 
the clotting factor concentrates19,20.  These costs can be >$300,000 USD per year21.  Gene 
therapy offers an opportunity for a “one and done” intervention and, if it allows for 
discontinuation of prophylaxis, would result in enormous cost savings over the course of a 
lifetime.  In addition, due to the costs of care and health care access challenges in the 
developing world, >75% of individuals around the globe have limited or no access to any 
factor replacement therapy22.  A gene therapy intervention that could convert those with 
severe disease to a mild phenotype would dramatically alter the outcomes for hemophilia 
around the world. 
 
Why target the liver for gene expression? 
 The liver is a central organ for rare diseases with >400 described rare monogenic 
disorders associated with the liver, many of which can be cured through orthotopic liver 
transplantation23.  There are a subset of these monogenic diseases associated with the liver 
that are well-suited to gene therapy.  These include hemophilia A and B because of the 
following characteristics: a well-understood disease biology, restoration of protein levels to 
as little as 5-10% is clinically meaningful, the availability of preclinical models, well-described 
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biomarkers, readily identifiable patients, a short time to the primary outcome measure 
(plasma factor activity level) in order to shorten the time to proof of concept, and the 
opportunity for orphan drug designation to encourage research and development toward 
commercialization (Figure 2).  In contrast, caution remains in targeting the liver as it is 
unknown how gene therapy would affect the risk for liver cancer, especially in a population 
with existing pathology from prior hepatitis infection.  Malignancy was an issue with some 
early gene therapy trials targeting hematopoietic stem cells, however, the mechanism 
appeared to be related to the use of retrovirus vectors which integrated into target cell 
chromosomes leading to activation of cellular proto-oncogenes. Such risk could be 
minimized by adopting non-insertional (ie. non-integrative) approaches24. 
 
Which vectors efficiently target the liver? 
 The primary tools for gene transfer have included non-viral vectors, retroviral vectors, 
adenoviral vectors, lentiviral vectors and adeno-associated viral vectors.  Each of these can 
target the liver and have their distinct advantages and disadvantages (see reviews25-27).  
Adeno-associated virus (AAV) is a non-enveloped parvovirus that was discovered as an 
accompanying virion to adenovirus infection, shows widespread infection in the human 
population and yet is not associated with any pathogenic disease28.  Wild-type AAV contains 
overlapping genes which encode the replication (rep) and capsid (cap) proteins between two 
inverted terminal repeats (ITRs).  Significantly, the rep and cap genes can be provided in 
trans, thus the genome can be replaced with an expression cassette for a therapeutic protein 
between the ITRs.  These recombinant AAV (rAAV) vectors have been engineered to 
remove their integrative capacity such that they persist intracellulary almost exclusively as 
episomal chromatin to provide a template leading to durable expression of the therapeutic 
protein.  That integration events into the host genome are rare is a distinct safety advantage 
  
 
This article is protected by copyright. All rights reserved. 
 
10 
for rAAV over retroviral and lentiviral vectors.   Dozens of naturally occurring and genetically 
engineered AAV capsids (the protein shell of the virus) have been characterized.  Small 
differences in the capsid sequence (characterized by serotyping) can significantly influence 
the tissue tropism of the vector and can therefore be exploited to improve the efficacy of the 
gene transfer.  This has identified rAAV vectors with high tropism to the liver29.  Other 
distinctive advantages for rAAV vectors have been their capacity to transduce post-mitotic 
cells, a low risk for germline transmission with systemic delivery and a reduced inflammatory 
response.  Disadvantages include a cumbersome production system, a compact size which 
limits the capacity to accommodate larger therapeutic gene cassettes and significant pre-
existing humoral immunity in the population.  Overall, the relative efficacy and safety of rAAV 
vectors has made them the most highly suited for clinical gene therapy and the first to 
commercialization (AAV-based treatment for familial lipoprotein lipase deficiency30).  
 
Observations from early clinical trials in hemophilia 
 The earliest gene therapy trial for hemophilia B was conducted in China using a 
retroviral vector that transduced autologous skin fibroblasts with a FIX construct ex vivo that 
was then subsequently injected into subjects31.  This achieved transient expression of FIX up 
to 2% with partial correction of the bleeding phenotype.  A subsequent trial utilized 
intramuscular injection but failed to achieve persistent elevations of FIX in the plasma32 that 
was then followed by intravascular delivery of rAAV into the hepatic artery33.  This led to 
expression of FIX between 10-12%.  However, the expression was transient over several 
weeks with loss of expression following an asymptomatic and self-limited elevation in liver 
transaminases.  This was not observed in preclinical animal models.  Several hypotheses 
have been proposed for this observation29.  First, capsid antigen presentation on the 
hepatocyte surface with accompanying memory T-cell activation may lead to clearance of 
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AAV-transduced cells.  Secondly, expression of rep/cap from vector impurities or translation 
of alternative reading frames within the expression cassettes may trigger cytotoxic T cells 
directed against transduced cells.  Lastly, the mechanism whereby AAV is taken up by 
antigen presenting cells may result in higher immunogenicity for specific serotypes.   In an 
attempt to abrogate these mechanisms, recent trials have explored the use of alternative or 
engineered serotypes34, strategies to reduce the AAV vector dose required to achieve 
therapeutic efficacy, and utilization of immunosuppression35.   
 
Academic proof of concept for hemophilia gene therapy 
 After more than a decade of preclinical and clinical trial exploration with AAV, 
academic proof of concept for hemophilia gene therapy was achieved in a clinical trial for 
hemophilia B conducted through a collaboration between the University College of London 
and St. Jude Children’s Research Hospital36.  This trial utilized a self-complementary AAV8 
serotype which had shown strong liver tropism, rapid uncoating of the capsid, and 
instantaneous transgene expression upon nuclear localization of the virion.  The expression 
cassette utilized a codon-optimized FIX gene construct driven by a short liver-specific 
promoter.   These modifications lead to enhanced transduction efficiency in preclinical 
studies and the hypothesis was that a meaningful clinical effect could be achieved with lower 
vector dose delivered via peripheral infusion.  Indeed, in the clinical trial, a dose-dependent 
rise in FIX to 1-6% of normal was achieved with an average drop of bleeding episodes from 
15.5 to 1.5 per year, an average 92% decrease in replacement FIX use and durable effect 
that is now approaching 5 years37.  However, four of the six patients in the highest dose 
cohort developed an asymptomatic rise in liver transaminases (primarily the ALT) with a 
concomitant decline of FIX activity.  The investigators treated these subjects with a short 
course of oral prednisolone resulting in stabilization of the FIX levels and resolution of the 
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transaminase elevation.  The success of this clinical trial has driven an explosive activity of 
hemophilia gene therapy programs across the world.  
 
Ongoing hemophilia clinical trial programs 
 The ongoing gene therapy clinical trial programs are each building on the success 
reported by Nathwani et al. to further improve safety and efficacy as well as broadening the 
eligibility of subjects.  Pre-existing neutralizing antibodies to AAV would reduce the efficacy 
of viral transduction and the prevalence in potential subjects can vary widely by age, 
geography and AAV serotype38,39.  Thus, additional AAV serotypes have been explored 
including those with engineered capsids. Several programs are leveraging recombinant 
technologies in attempts to achieve improved transduction efficiency while minimizing the 
vector dosage.  Strategies have included enhancements in codon optimization and utilization 
of bioengineered variants of the FVIII (B domain deletion40) and FIX constructs 
(“hyperactive” Padua FIX variant, R338L41) to facilitate improved viral packaging and higher 
specific activity.  The Padua FIX variant was adopted as it was identified as a naturally 
occurring FIX variant in a family with thrombophilia, exhibits ~5- to 7-fold increased FIX 
specific activity, and allows for reduced vector dosing without sacrificing efficacy as 
determined by plasma FIX levels.  Immunosuppression strategies have included early 
introduction of prednisolone at first evidence of transaminase elevation and even 
prophylactic steroids.  The phase 1/2 clinical trials that have reported results11,42-46 are 
summarized in Figure 3.  These trials have demonstrated reassuring safety across a broad 
age range of subjects and evidence of dose-response, with the majority of subjects in the 
higher dose cohorts achieving FIX and FVIII levels that are in the mild hemophilia range 
(>5%) or higher.   Notably, 6 of 8 patients in the highest dose cohort of the AAV-FVIII trial 
achieved curative FVIII expression (>50%)46.  The expectation is that these programs and 
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others will move forward in clinical development with phase 3 pivotal trials toward 
commercialization.   
 
Future directions for gene therapy 
Genome editing 
As hemophilia therapy has evolved from protein replacement to gene replacement, 
the next natural step would be gene correction.  This has now become a reality through 
fundamental discoveries and engineering breakthroughs that have produced a toolkit of 
reagents for genome editing47.  The four basic platforms are engineered meganucleases, 
zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs) and 
clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 nucleases.  The 
basic premise of these technologies is to introduce a site-specific DNA double-stranded 
break (DSB) and then allow the cell’s own endogenous repair machinery to repair the 
break.  The 2 major repair pathways are non-homologous end joining (NHEJ) and homology-
directed repair (HDR).  NHEJ is error prone and often results in small insertions or deletions 
(“indels”) at the cleavage site which can lead to functional disruptions in the targeted 
sequence.  HDR requires a donor template to facilitate the repair.  Whereas natural HDR 
relies on homologous sister chromatids to serve as the template, in genome editing, an 
extrachromosomal donor template may be used to integrate a DNA sequence of choice 
adjacent to the induced DSB.  This then becomes a mechanism by which gene replacement 
or editing can be achieved.  This technology has been applied in which an AAV vector is 
utilized to deliver ZFNs which mediate site-specific integration of a FIX transgene within the 
albumin gene locus48. This allows the transgene to come under control of the native 
expression machinery within the liver and is deemed a “safe harbor” for genetic 
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integration, avoiding random integration with potential deleterious effects.  A distinct 
advantage of this strategy is that transgene expression would be anticipated to remain stable 
with cell division and turnover (versus current non-integrative strategies) and may be more 
amenable to gene therapy in younger subjects.  This strategy has resulted in expression of 
therapeutic FIX levels (20-50%) in non-human primates and a Phase 1/2 clinical trial is 
ongoing49.  Cas9 has been difficult to package in AAV due to its large size but truncated 
guide RNAs and computationally designed hepatocyte specific promoters can lead to liver-
specific and targeted site-specific indels in murine models50.  However, it’s currently 
impractical in the context of a clinical gene therapy program to design reagents to correct 
each point mutation that can cause hemophilia.  The “safe harbor” approach obviates the 
need to design reagents for each point mutation. 
 
Other cellular targets for gene therapy for hemophilia 
 Patient-derived induced pluripotent stem cells (iPSCs) are a promising area of 
investigation for cell-based therapy for hemophilia.  These can be derived from human 
dermal fibroblasts, although without modification, would retain the genetic defect causing the 
subject’s hemophilia.  However, the defective gene can be corrected ex vivo through 
genome editing.  In one example, TALENs were used to invert a 140-kbp chromosomal 
segment of the F8 gene in human iPSCs, thus recapitulating the commonest genetic cause 
of severe hemophilia A51.  These model hemophilia A iPSC cell lines were then reverted 
back to the wild-type state through a similar strategy.  The ex vivo approach also allows for 
characterization of the cell lines to ensure no off-target effects.  This genomic rearrangement 
would likely be even more efficient with CRISPR/Cas9.  However, this is evidence that 
engineered endonucleases could be used to rearrange large genomic sequences in iPSCs 
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and provides proof of concept that genomically modified iPSCs could be used to correct a 
genetic defect like hemophilia through autologous stem cell therapy. 
 Hematopoietic stem cell (HSC)-directed gene therapy is achieved through ex vivo 
transduction of autologous HSCs, typically utilizing integrating viral vectors such as retroviral 
or lentiviral vectors.  The transduced HSCs are then transplanted into an HSC-depleted 
recipient after conditioning.  Since HSCs undergo both self-renewal and differentiation, they 
then create a reservoir of transgene-expressing cells that persist in the bone marrow and are 
capable of amplifying within the recipient up to 106-fold.  One strategy used lentivirus to 
transduce HSCs ex vivo with bioengineered high-expression FVIII transgenes that corrected 
the bleeding phenotype of hemophilia A mice52. 
  Activated platelets mediate the primary response to vascular injury by adhering to 
the site of injury and secrete biologically active proteins.  It was hypothesized that a FVIII 
transgene under control of a megakaryocyte-specific promoter would lead to a locally 
inducible mechanism to maintain hemostasis at sites of vascular injury in hemophilia A.  
Furthermore, since platelets would provide a confined site of synthesis and storage within 
platelets, FVIII would be protected from inhibition from anti-FVIII antibodies.  This is an 
important feature as subjects with inhibitors to FVIII have been excluded from all clinical 
gene therapy trials to date.  HSC-targeted lentiviral-mediated gene transfer of FVIII leads to 
trafficking of FVIII to the alpha-granule compartment of platelets and correction of the 
bleeding phenotype in murine and canine models of hemophilia.  In mice, hemostasis was 
achieved even in the presence of high titer inhibitory antibodies53. FVIII expressed in this 
manner also did not elicit the formation of inhibitory antibodies in a line of dogs with 
hemophilia A previously known to readily form inhibitors to human FVIII54.  A phase 1 clinical 
trial protocol has been proposed that would target subjects with hemophilia A and refractory 
high titer antibodies.  A recent study demonstrated in a preclinical model that intra-osseus 
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injection of a lentiviral vector was capable of transducing bone marrow cells in situ with a 
FVIII transgene and target to platelets55.  Notably, this approach would not require any pre-
transplant conditioning which is still a significant drawback for HSC-targeted approaches. 
 
Remaining questions 
 The cytotoxic cell-mediated immune response remains a stubborn challenge for all of 
the clinical trial programs.  There is still debate as to the underlying mechanism(s), whether 
the decline in factor expression can be abrogated with steroids in all cases, and whether a 
reactive or prophylactic approach to instituting steroids is best.  Is the ALT increase the best 
biomarker or could new biomarkers provide an earlier signal that could trigger an more 
consistent therapeutic response? 
 Given the enhanced pharmacokinetic characteristics of the most recently approved 
recombinant clotting factors, particularly the extended half-life FIX products that have been 
able to maintain trough factor IX levels as high as 20% with weekly dosing schedules, what 
level of durable expression does a gene therapy intervention have to achieve to be a viable 
option?  Current outcomes show durable response over ~5 years, but considering that 
exposure to AAV universally leads to an immunological response that may preclude re-
treatment, are the current gene therapy strategies likely to achieve durable expression over 
a lifetime? 
What will be the potential application in children? It has been widely demonstrated 
that the earlier that joint bleeding can be abrogated, the better likelihood of joint preservation 
into adulthood.  However, what long term outcome data will be necessary in order to give 
confidence to apply this intervention in younger children.  Will hepatocellular turnover limit 
durable expression if gene therapy is applied early in life? 
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 The economics of hemophilia therapy are an area of intense focus by commercial 
and public payer systems.  Gene therapy certainly offers to dramatically reduce or even 
eliminate the need for regular factor replacement lifelong.  How should this be valued and 
who should pay for what may be the definitive gene therapy intervention?  Moreover, in 
nationalized health systems and in the developing world, should gene therapy be the 
preferable intervention to a lifetime of factor replacement therapy?  Even considering a “one 
and done” approach and the anticipation of long-term savings, is it likely that nationalized 
health systems, particularly within economically disadvantaged countries, would be able to 
afford this technology?  
 These questions will need to be addressed through the phase 3 pivotal trial programs 
and considered by regulators, payers and consumer advocacy groups.  Even with 
successfully phase 3 programs, there may be considerable challenges in the scalability of 
individual gene therapy programs to address the needs globally.  However, these are likely 
to be surmountable hurdles as we enter this next “golden era” for treatment for hemophilia. 
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Figure Legends: 
 
Figure 1. AAV and the Liver 
NAbs, neutralizing antibodies 
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Figure 2. Evolution of Hemophilia Gene Therapy 
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Figure 3. Gene therapy trials for Hemophilia A and B with reported results. 
sc, self-complementary; h, human; co, codon optimized; BDD, B domain deleted; ALT, alanine 
aminotransferase 
 
 
 
 
